POSC76 Cost-Utility Analysis of Pegaspargase for the Treatment of Acute Lymphoblastic Leukemia in Greece

To assess the cost-utility of pegaspargase versus L- asparaginase, both followed by Erwinase in therapy sequence, as treatment option for pediatric, adolescents and adult patients with acute lymphoblastic leukemia (ALL) Greece. A published model comprised a decision tree (DT) state-transition Markov was adapted from public payer perspective to compare sequence L-asparaginase. The DT included regimen cycles potential hypersensitivity asparaginase. As experience survival outcome during after treatment, also incorporated parallel extrapolate over life-time horizon. Efficacy safety data, well utility values, were extracted literature. Direct costs pertaining drug acquisition, administration, management considered analysis (€,2020). Resource consumption associated each based on experts’ advice. Model outcomes patient quality-adjusted life years (QALYs), total incremental cost-effectiveness ratios (ICER) per QALY gained. All future discounted at 3.5% annum. Sensitivity analyses used explore impact changing input data. showed that estimated produce 0.05 additional QALYs (18.12 18.07) lower cost -€1,698 compared L-asparaginase, indicating dominant strategy (improve reduced costs) Deterministic sensitivity confirmed cost-effective profile. At defined willingness-to-pay threshold €54,000/QALY gained, probabilistic had 100% probability being relative asparaginase sequence. Pegaspargase found be less costly more effective (in terms QALYs) relation representing strategic Greek ALL.